AR119331A1 - Ligandos para el antígeno de membrana específico de próstata (psma) y usos de los mismos - Google Patents

Ligandos para el antígeno de membrana específico de próstata (psma) y usos de los mismos

Info

Publication number
AR119331A1
AR119331A1 ARP200101868A ARP200101868A AR119331A1 AR 119331 A1 AR119331 A1 AR 119331A1 AR P200101868 A ARP200101868 A AR P200101868A AR P200101868 A ARP200101868 A AR P200101868A AR 119331 A1 AR119331 A1 AR 119331A1
Authority
AR
Argentina
Prior art keywords
psma
group
ligands
specific membrane
membrane antigen
Prior art date
Application number
ARP200101868A
Other languages
English (en)
Spanish (es)
Inventor
Maurizio F Mariani
Lorenza Fugazza
Daniela Chicco
Martin Gilbert Pomper
Sangeeta Ray
Original Assignee
Advanced Accelerator Applications Italy Srl
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications Italy Srl, Univ Johns Hopkins filed Critical Advanced Accelerator Applications Italy Srl
Publication of AR119331A1 publication Critical patent/AR119331A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/38—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP200101868A 2019-07-02 2020-07-01 Ligandos para el antígeno de membrana específico de próstata (psma) y usos de los mismos AR119331A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19184015 2019-07-02

Publications (1)

Publication Number Publication Date
AR119331A1 true AR119331A1 (es) 2021-12-09

Family

ID=67145647

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101868A AR119331A1 (es) 2019-07-02 2020-07-01 Ligandos para el antígeno de membrana específico de próstata (psma) y usos de los mismos

Country Status (16)

Country Link
US (1) US20230226227A1 (cg-RX-API-DMAC7.html)
EP (1) EP3993837A1 (cg-RX-API-DMAC7.html)
JP (2) JP7805170B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220044496A (cg-RX-API-DMAC7.html)
CN (3) CN120441497A (cg-RX-API-DMAC7.html)
AR (1) AR119331A1 (cg-RX-API-DMAC7.html)
AU (3) AU2020299974A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021026812A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144557A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003525A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017708A2 (cg-RX-API-DMAC7.html)
IL (1) IL289039B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022000136A (cg-RX-API-DMAC7.html)
PH (1) PH12021553284A1 (cg-RX-API-DMAC7.html)
TW (1) TW202114742A (cg-RX-API-DMAC7.html)
WO (1) WO2021001360A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297323A (en) * 2020-04-29 2022-12-01 Novartis Ag Methods for radiological labeling of psma-binding ligands and their kits
WO2022108992A1 (en) * 2020-11-17 2022-05-27 The Johns Hopkins University Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma
EP4746926A2 (en) 2023-07-21 2026-05-27 Novartis AG Psma-targeting radioligand treatment regimen
WO2025125469A1 (en) 2023-12-13 2025-06-19 Swiss Rockets Ag Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor
WO2026125645A1 (en) 2024-12-12 2026-06-18 Swiss Rockets Ag Radiopharmaceuticals for use in the treatment of high-risk localized prostate cancer
WO2026159621A1 (en) 2025-01-23 2026-07-30 Novartis Ag Treatment regimen using psma-binding radioligands in combination with androgen receptor pathway inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2415709A1 (en) 2000-07-11 2003-01-10 Bml, Inc. Remedies for bone diseases
JP5843338B2 (ja) * 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
AU2014336638C1 (en) * 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
KR20250057132A (ko) * 2016-03-22 2025-04-28 더 존스 홉킨스 유니버시티 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
US11478558B2 (en) * 2017-05-30 2022-10-25 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
WO2019157037A1 (en) * 2018-02-06 2019-08-15 The Johns Hopkins University Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
US20210338846A1 (en) * 2018-07-30 2021-11-04 The Johns Hopkins University Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy

Also Published As

Publication number Publication date
CO2021017708A2 (es) 2022-05-20
JP2025165975A (ja) 2025-11-05
KR20220044496A (ko) 2022-04-08
CN114341118A (zh) 2022-04-12
AU2025271182A1 (en) 2025-12-18
JP7805170B2 (ja) 2026-01-23
CN120441497A (zh) 2025-08-08
AU2024200850B2 (en) 2025-09-04
TW202114742A (zh) 2021-04-16
PH12021553284A1 (en) 2022-08-01
AU2024200850A1 (en) 2024-02-29
MX2022000136A (es) 2022-04-27
WO2021001360A1 (en) 2021-01-07
CN120441498A (zh) 2025-08-08
AU2020299974A1 (en) 2022-01-27
JP2022538478A (ja) 2022-09-02
IL289039B2 (en) 2026-07-01
BR112021026812A2 (pt) 2022-02-22
IL289039B1 (en) 2026-03-01
CL2021003525A1 (es) 2022-10-21
US20230226227A1 (en) 2023-07-20
IL289039A (en) 2022-02-01
CA3144557A1 (en) 2021-01-07
EP3993837A1 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
AR115326A1 (es) Inhibidores heterobicíclicos de mat2a y métodos de uso para tratar el cáncer
AR122783A2 (es) Inhibidores de kras g12c y métodos para su uso
AR117544A1 (es) Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer
AR115296A1 (es) Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer
AR117398A1 (es) Inhibidores de la señalización mediada por tirosina cinasa 2
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
MX2021005808A (es) Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer.
MX2021014913A (es) Compuestos de pirrolidina.
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
AR110056A2 (es) Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
AR109349A1 (es) Compuestos y usos
CL2021000175A1 (es) Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR107154A1 (es) Estimuladores de guanilato ciclasa soluble
AR110789A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
AR110790A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
MX392700B (es) Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados.
AR115007A1 (es) Derivados de triazolona o sales de los mismos y composiciones farmacéuticas que comprenden los mismos
ECSP088467A (es) Formulaciones de quinolinonas
Önen-Bayram et al. 3-Propionyl-thiazolidine-4-carboxylic acid ethyl esters: a family of antiproliferative thiazolidines
JP2019513829A5 (cg-RX-API-DMAC7.html)
AR040078A1 (es) Diaminotiazoles
JOP20250076A1 (ar) طرق لعلاج السرطان باستخدام مشتقات أيزو كوينولين أو 6-آزا-كوينولين
AR081034A1 (es) Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central